Clinical Scorecard: Association of Serum Syndecan-1 Levels with Severity of Coronary Artery Calcification and Intradialytic Hypotension in Older Patients Undergoing Hemodialysis

At a Glance

Key Highlights

• Serum syndecan-1 levels significantly higher in MHD patients compared to controls (P < 0.001)
• Strong correlation between serum syndecan-1 and coronary artery calcium scores (r = 0.75, P < 0.001)
• Elevated syndecan-1 independently associated with greater CAC severity (Adjusted OR = 1.148, P < 0.001)
• Exploratory SDC1 threshold of 33.5 pg/mL linked to higher CAC prevalence (86.9% vs. 7.4%, P < 0.001)
• Increased frequency of intradialytic hypotension episodes associated with elevated syndecan-1 levels (P < 0.001)

Guideline-Based Recommendations

Diagnosis

• Assess serum syndecan-1 levels as a potential biomarker for endothelial dysfunction in elderly MHD patients
• Evaluate coronary artery calcification severity using computed tomography coronary artery calcium scores

Management

• Monitor serum syndecan-1 levels in conjunction with clinical markers of cardiovascular health

Monitoring & Follow-up

• Regularly review intradialytic hypotension episodes in relation to serum syndecan-1 levels

Risks

• Increased risk of cardiovascular events and mortality associated with elevated coronary artery calcification

Patient & Prescribing Data

Elderly maintenance hemodialysis patients aged 60-85 years

Further prospective validation of syndecan-1 as a biomarker for vascular and hemodynamic instability is needed

Clinical Best Practices

• Incorporate serum syndecan-1 assessment in routine evaluations of elderly MHD patients
• Utilize coronary artery calcium scoring for risk stratification in cardiovascular disease management

Related Resources & Content

• Study on serum syndecan-1 and CAC